Buy or Sell ? Support and Resistance
What is MACD and how to read it?
How RSI can help?
RSI : 000
0399.HK Stock Summary
In the News
0399.HK Financial details
Company Rating
Sell
Market Cap
346.36M
Income
95.48M
Revenue
11.5M
Book val./share
-0.41
Cash/share
0
Dividend
-
Dividend %
-
Employees
20
Optionable
No
Shortable
Yes
Earnings
29 Nov 2023
P/E
-1.24
Forward P/E
-
PEG
0.13
P/S
42.97
P/B
-0.38
P/C
-
P/FCF
-19.67
Quick Ratio
-
Current Ratio
0.01
Debt / Equity
-1.66
LT Debt / Equity
2.02
-
-
EPS (TTM)
0.01
EPS next Y
-
EPS next Q
-
EPS this Y
-200%
EPS next Y
-
EPS next 5Y
-
EPS last 5Y
-1.14%
Revenue last 5Y
-15.36%
Revenue Q/Q
100%
EPS Q/Q
974.38%
-
-
-
-
SMA20
-
SMA50
-
SMA100
-
Inst Own
-
Inst Trans
-
ROA
-18%
ROE
37%
ROC
-0.09%
Gross Margin
11%
Oper. Margin
-256%
Profit Margin
-3043%
Payout
-
Shs Outstand
1.72B
Shs Float
1.29B
-
-
-
-
Target Price
-
52W Range
0.19-0.37
52W High
-
52W Low
-
RSI
45
Rel Volume
-
Avg Volume
69.54K
Volume
100
Perf Week
-1.48%
Perf Month
-0.99%
Perf Quarter
-
Perf Half Y
-16.67%
-
-
-
-
Beta
-0.123
-
-
Volatility
0%, 0%
Prev Close
0%
Price
0.2
Change
0.5%
0399.HK Financial Performance
Yearly Fundamentals Overview
Last date of statement is 2023-03-31
Metric | History | 2019-03-31 | 2020-03-31 | 2021-03-31 | 2022-03-31 | 2023-03-31 |
---|---|---|---|---|---|---|
2.02K | 2.02K | 2.02K | 2.02K | 2.02K | ||
Revenue per share | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | |
Net income per share | -0.18 | -0.28 | -0.27 | 0.17 | -0.17 | |
Operating cash flow per share | -0.02 | -0.02 | -0.02 | -0.01 | -0.01 | |
Free cash flow per share | -0.02 | -0.02 | -0.02 | -0.01 | -0.01 | |
Cash per share | 0.01 | 0.02 | 0.01 | 0 | 0 | |
Book value per share | -0.05 | -0.27 | -0.41 | -0.31 | -0.54 | |
Tangible book value per share | -0.4 | -0.55 | -0.69 | -0.56 | -0.84 | |
Share holders equity per share | -0.05 | -0.27 | -0.41 | -0.31 | -0.54 | |
Interest debt per share | 0.57 | 0.64 | 0.81 | 0.65 | 0.97 | |
Market cap | 592.86M | 373.33M | 364.5M | 260.78M | 304.55M | |
Enterprise value | 1.29B | 1.14B | 1.35B | 1.2B | 1.49B | |
P/E ratio | -2.28 | -0.92 | -0.92 | 0.88 | -1.24 | |
Price to sales ratio | 31.89 | 25.61 | 24 | 23.4 | 37.72 | |
POCF ratio | -20.1 | -10.31 | -14.58 | -21.14 | -17.26 | |
PFCF ratio | -20.1 | -10.31 | -14.58 | -21.14 | -17.26 | |
P/B Ratio | -7.91 | -0.96 | -0.61 | -0.47 | -0.38 | |
PTB ratio | -7.91 | -0.96 | -0.61 | -0.47 | -0.38 | |
EV to sales | 69.15 | 78.21 | 88.68 | 107.54 | 185.01 | |
Enterprise value over EBITDA | -111.33 | -46.03 | -70.77 | -53.93 | -79.38 | |
EV to operating cash flow | -43.58 | -31.48 | -53.87 | -97.17 | -84.69 | |
EV to free cash flow | -43.58 | -31.48 | -53.87 | -97.17 | -84.69 | |
Earnings yield | -0.44 | -1.09 | -1.09 | 1.14 | -0.81 | |
Free cash flow yield | -0.05 | -0.1 | -0.07 | -0.05 | -0.06 | |
Debt to equity | -9.47 | -2.02 | -1.67 | -1.71 | -1.5 | |
Debt to assets | 0.45 | 0.56 | 0.71 | 0.68 | 0.86 | |
Net debt to EBITDA | -59.98 | -30.96 | -51.62 | -42.2 | -63.2 | |
Current ratio | 1.37 | 0.6 | 0.04 | 0.19 | 0.01 | |
Interest coverage | -0.09 | -0.18 | -0.11 | -0.13 | -0.09 | |
Income quality | 0.11 | 0.16 | 0.12 | -0.34 | 0.07 | |
Dividend Yield | 0 | 0 | 0 | 0 | 0 | |
Payout ratio | 0 | 0 | 0 | 0 | 0 | |
Sales general and administrative to revenue | 1.44 | 1.55 | 1.11 | 1.55 | 2.11 | |
Research and developement to revenue | 0.1 | 0.78 | 0.4 | 0.74 | 0.59 | |
Intangibles to total assets | 0.87 | 0.97 | 0.98 | 0.98 | 0.99 | |
Capex to operating cash flow | 0 | 0 | 0 | 0 | 0 | |
Capex to revenue | 0 | 0 | 0 | 0 | 0 | |
Capex to depreciation | 0 | 0 | 0 | 0 | 0 | |
Stock based compensation to revenue | 0 | 0 | 0 | 0 | 0 | |
Graham number | 0.45 | 1.29 | 1.57 | 1.09 | 1.43 | |
ROIC | -0.03 | -0.12 | -0.1 | -0.5 | -0.05 | |
Return on tangible assets | -1.27 | -8.93 | -13.2 | 13.62 | -22.7 | |
Graham Net | -0.51 | -0.56 | -0.7 | -0.56 | -0.85 | |
Working capital | 12.14M | -28.35M | -771.87M | -80.82M | -1.14B | |
Tangible asset value | -578.41M | -805.45M | -1.01B | -977.96M | -1.23B | |
Net current asset value | -739.4M | -808.92M | -1.02B | -980.78M | -1.23B | |
Invested capital | -9.47 | -2.02 | -1.67 | -1.71 | -1.5 | |
Average receivables | 10.59M | 18.39M | 15.47M | 12.41M | 7.96M | |
Average payables | 15.81M | 15.73M | 7.87M | 6.82M | 6.09M | |
Average inventory | 0 | 0.5 | 1 | 1 | 0.5 | |
Days sales outstanding | 415.8 | 390.74 | 368.22 | 311.26 | 289.79 | |
Days payables outstanding | 459.75 | 288.76 | 145.08 | 294.9 | 203.41 | |
Days of inventory on hand | 0 | 0 | 0 | 0 | 0 | |
Receivables turnover | 0.88 | 0.93 | 0.99 | 1.17 | 1.26 | |
Payables turnover | 0.79 | 1.26 | 2.52 | 1.24 | 1.79 | |
Inventory turnover | 0 | 12.96M | 13.78M | 10.09M | 0 | |
ROE | 3.47 | 1.04 | 0.66 | -0.54 | 0.31 | |
Capex per share | 0 | 0 | 0 | 0 | 0 |
Quarterly Fundamentals Overview
Last date of statement is 2023-09-30 for Q2
Metric | History | 2022-09-30 | 2022-12-31 | 2023-03-31 | 2023-06-30 | 2023-09-30 |
---|---|---|---|---|---|---|
2.02K | 2.02K | 2.02K | 2.02K | 2.02K | ||
Revenue per share | 0 | 0 | 0 | 0 | 0 | |
Net income per share | -0.08 | -0.04 | -0.09 | 0.01 | 0.13 | |
Operating cash flow per share | 0 | -0.01 | -0.01 | 0 | 0 | |
Free cash flow per share | 0 | -0.01 | -0.01 | 0 | 0 | |
Cash per share | 0 | 0 | 0 | 0 | 0 | |
Book value per share | -0.45 | -0.54 | -0.54 | -0.08 | -0.41 | |
Tangible book value per share | -0.75 | -0.84 | -0.84 | -0.13 | -0.71 | |
Share holders equity per share | -0.45 | -0.54 | -0.54 | -0.08 | -0.41 | |
Interest debt per share | 0.8 | 0.07 | 0.9 | 0.08 | 0.77 | |
Market cap | 308.94M | 292.84M | 304.55M | 1.6B | 349.94M | |
Enterprise value | 1.36B | 291.51M | 1.49B | 1.6B | 1.34B | |
P/E ratio | -0.67 | -1.13 | -0.59 | 4.14 | 0.45 | |
Price to sales ratio | 74.66 | 148.76 | 77.36 | 859.7 | 93.89 | |
POCF ratio | -108.1 | -39.62 | -20.6 | -731.86 | -79.93 | |
PFCF ratio | -108.1 | -39.62 | -20.6 | -731.86 | -79.93 | |
P/B Ratio | -0.46 | -0.37 | -0.38 | -2.66 | -0.58 | |
PTB ratio | -0.46 | -0.37 | -0.38 | -2.66 | -0.58 | |
EV to sales | 329.28 | 148.09 | 379.46 | 859.24 | 360.85 | |
Enterprise value over EBITDA | -201.35 | -47.95 | -121.63 | -607.49 | -246.36 | |
EV to operating cash flow | -476.75 | -39.44 | -101.07 | -731.47 | -307.19 | |
EV to free cash flow | -476.75 | -39.44 | -101.07 | -731.47 | -307.19 | |
Earnings yield | -0.37 | -0.22 | -0.43 | 0.06 | 0.55 | |
Free cash flow yield | -0.01 | -0.03 | -0.05 | 0 | -0.01 | |
Debt to equity | -1.59 | -0.12 | -1.5 | -1.12 | -1.66 | |
Debt to assets | 0.76 | 0.07 | 0.86 | 0.49 | 0.72 | |
Net debt to EBITDA | -155.7 | 0.22 | -96.83 | 0.33 | -182.26 | |
Current ratio | 0.02 | 0.01 | 0.01 | 0.02 | 0.02 | |
Interest coverage | -0.07 | 0 | -0.11 | 0 | -0.05 | |
Income quality | 0.02 | 0.11 | 0.11 | -0.02 | -0.02 | |
Dividend Yield | 0 | 0 | 0 | 0 | 0 | |
Payout ratio | 0 | 0 | 0 | 0 | 0 | |
Sales general and administrative to revenue | 0.8 | 2.65 | 1.33 | 1.69 | 0.84 | |
Research and developement to revenue | 0.36 | 0.83 | 0.83 | 0.08 | 0.08 | |
Intangibles to total assets | 0.99 | 0.99 | 0.99 | 0.99 | 0.99 | |
Capex to operating cash flow | 0 | 0 | 0 | 0 | 0 | |
Capex to revenue | 0 | 0 | 0 | 0 | 0 | |
Capex to depreciation | 0 | 0 | 0 | 0 | 0 | |
Stock based compensation to revenue | 0 | 0 | 0 | 0 | 0 | |
Graham number | 0.9 | 0.74 | 1.04 | 0.14 | 1.11 | |
ROIC | -0.02 | 0.01 | -0.03 | -0.04 | -0.02 | |
Return on tangible assets | -6.36 | -6.01 | -12.01 | 10.77 | 21.53 | |
Graham Net | -0.76 | -0.85 | -0.85 | -0.13 | -0.71 | |
Working capital | -808.1M | -1.14B | -1.14B | -369.17M | -369.17M | |
Tangible asset value | -1.1B | -1.23B | -1.23B | -1.04B | -1.04B | |
Net current asset value | -1.1B | -1.23B | -1.23B | -1.04B | -1.04B | |
Invested capital | -1.59 | -0.12 | -1.5 | -1.12 | -1.66 | |
Average receivables | 0 | 7.71M | 6.29M | 6M | 5.59M | |
Average payables | 0 | 5.99M | 4.02M | 3.77M | 3.52M | |
Average inventory | 0 | -4.63M | 0 | 0 | 0 | |
Days sales outstanding | 201.21 | 281.96 | 146.56 | 270.07 | 135.04 | |
Days payables outstanding | 192.57 | 206.85 | 103.42 | 189.3 | 94.65 | |
Days of inventory on hand | -224 | 0 | 0 | 0 | 0 | |
Receivables turnover | 0.45 | 0.32 | 0.61 | 0.33 | 0.67 | |
Payables turnover | 0.47 | 0.44 | 0.87 | 0.48 | 0.95 | |
Inventory turnover | -0.4 | 0 | 0 | 0 | 0 | |
ROE | 0.17 | 0.08 | 0.16 | -0.16 | -0.32 | |
Capex per share | 0 | 0 | 0 | 0 | 0 |
0399.HK Frequently Asked Questions
What is Innovative Pharmaceutical Biotech Limited stock symbol ?
Innovative Pharmaceutical Biotech Limited is a HK stock and trading under the symbol 0399.HK
What is Innovative Pharmaceutical Biotech Limited stock quote today ?
Innovative Pharmaceutical Biotech Limited stock price is $0.2 today.
Is Innovative Pharmaceutical Biotech Limited stock public?
Yes, Innovative Pharmaceutical Biotech Limited is a publicly traded company.